“…The ablation rate rises between 84 and 100% if only small breast lesions are considered. [12][13][14][15] Moreover, there are also studies on the laser thermal ablation of benign lesions, such as fibroadenomas 16,17 or as palliative therapy in inoperable or refusing surgery patients. 18 It is also important underline that LITT has already been widely standardized in several studies in the literature, both ex-vivo and in-vivo, on brain, bone, skin, gastrointestinal, liver, lung, pancreas, thyroid, retinal lesions, prostate and uterus [19][20][21][22][23][24][25][26] ; however the validation of tumor ablate therapy in breast clinical practice is still ongoing, more prospective studies addressing local failure rates, cosmesis, the effectiveness to detect residual untreated disease, and long-term patient satisfaction are required.…”